[Multihospital randomized study on adjuvant chemotherapy with mitomycin C and futraful or UFT in gastric cancer (Part 1). Comparison between futraful and UFT. North Kyushu Co-operative Study Group for Cancer Chemotherapy)].
The present study was undertaken to evaluate the effect of postoperative adjuvant chemotherapy for 232 cases of gastric cancer by a co-operative study group consisting of 21 hospitals. The present paper describes the side effects and the 2-year survival rates in patients. Side effects observed during long-term treatment with Futraful or UFT were considered to be minor, although incidence of toxicity in the UFT group was slightly higher than in the Futraful group. As for 2-year survival, elevated survival was found in stage III cases of poorly differentiated adenocarcinoma. This suggested that UFT is more useful than Futraful.
D000971:Antineoplastic Combined Chemotherapy Protocols; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011182:Postoperative Care; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil